Hemispherx Biopharma (HEB) Presents at Rodman & Renshaw Conference

Hemispherx Biopharma, Inc. (NYSE: HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection and the experimental immunotherapeutics/antivirals Ampligen. Alferon N Injection is the company’s injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. For more information, visit the company’s website at www.hemispherx.net